“…Many excellent and exhaustive studies have based this mechanism of catalysis and the structure of the catalytic site architecture to design several different classes of peptidomimetic inhibitors targeted against M pro of coronaviruses (including SARS) and other pathogenic viruses. Several M pro inhibitors have also been structurally characterized (Akaji et al, 2011;Bacha et al, 2008;Chu et al, 2006;Chuck et al, 2013;Grum-Tokars et al, 2008;Lee et al, 2007;Lee et al, 2009;Lee et al, 2005;Shan and Xu, 2005;Shao et al, 2007;Turlington et al, 2013;Verschueren et al, 2008;Wei et al, 2006;Yang et al, 2006;Yang et al, 2003;Yang et al, 2007;Zhang et al, 2010;Zhu et al, 2011).…”